comprehensive -WSS

comprehensive

author：comprehensive 2025-09-30 08:52:56 - browse：6

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Readout LOUD podcast: ALS dilemma, first MASH drug, and more

WSS

With fresh data, a dynamic duo powers Eli Lilly to new heights

EPA limits use of carcinogenic gas for sterilizing medical devices

Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

US intelligence assessment says Iran not currently developing nuclear weapons

Readout Newsletter: Bristol, Sangamo, Gilead, and more

First U.S. drug developed to treat liver disease MASH is approved

entertainment

comprehensive

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

UCLA team creates talking throat patch for voice disorders

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Neutralizing antibodies against HIV shows promise in children

Continuity nursing helped my family in our darkest PICU moments

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

Hepatitis C has a cure — but many Americans still lack access to it

John Green on his newest strategy for fighting tuberculosis

Anesthesiologist group: stop taking Ozempic before surgery

Medicare coverage of Wegovy, once blocked, now looks possible

leisure time

How to save health care price transparency rules

Male and female sex labels in research insufficient, scientists say

Boston's new lab space is opening empty

How to save health care price transparency rules

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Titanic submersible: What a 'catastrophic implosion' means and what officials found

leisure time

entertainment

focus

entertainment